Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EBT (2020 - 2026)

Journey Medical filings provide 6 years of EBT readings, the most recent being -$1.2 million for Q4 2025.

  • On a quarterly basis, EBT fell 178.82% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$11.4 million, a 22.18% increase, with the full-year FY2025 number at -$11.4 million, up 22.18% from a year prior.
  • EBT hit -$1.2 million in Q4 2025 for Journey Medical, up from -$2.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $16.9 million in Q3 2023 to a low of -$15.3 million in Q2 2021.
  • Median EBT over the past 5 years was -$3.9 million (2025), compared with a mean of -$5.1 million.
  • Biggest five-year swings in EBT: crashed 27063.46% in 2021 and later surged 267.67% in 2023.
  • Journey Medical's EBT stood at -$13.4 million in 2021, then rose by 20.77% to -$10.6 million in 2022, then surged by 81.02% to -$2.0 million in 2023, then skyrocketed by 178.43% to $1.6 million in 2024, then tumbled by 178.82% to -$1.2 million in 2025.
  • The last three reported values for EBT were -$1.2 million (Q4 2025), -$2.3 million (Q3 2025), and -$3.7 million (Q2 2025) per Business Quant data.